Home / GMP & GxP Audits
Independent audits that stand up to scrutiny.
Qualify and monitor suppliers with on-site, remote or hybrid audits that give your Quality Unit objective, evidence-based assurance.
Overview
Audit scope and sectors.
We audit across the pharmaceutical supply chain, scoped around your supplier, products and risk class.
- Supplier and site qualification audits
- Pre-inspection and mock inspections
- QMS and gap audits against ICH Q10 and EU GMP Chapter 1
- Due diligence audits for acquisitions, partnerships and technology transfer
- Laboratory and GLP audits
- Medical device audits to ISO 13485:2016
- CSV and data integrity audits against Annex 11 and ALCOA+
- For-cause and follow-up audits after a quality event or CAPA

Sectors
Coverage across the supply chain.
API manufacturers
ICH Q7 and EU GMP Part II audits, including starting materials, impurity control and data integrity.
Excipients and key starting materials
Risk-based audits of supplier quality systems, change control and traceability.
Finished dose manufacturers
Oral solid dose, parenteral and other dosage forms against EU GMP, MHRA and PIC/S expectations.
Packaging and contract sites
Contract manufacturers, packagers and testing partners.
Laboratories
Analytical, microbiology and GLP facilities.
Medical devices
Manufacturers audited to ISO 13485:2016 and the relevant device regulations.
Audit methodology
Assess, audit, report, improve.
Assess: define scope, risk and standards
Every engagement starts with a clear understanding of your supplier, products and the requirements that apply.
- Scoping call covering supplier, products, risk class, standards, location and audit mode
- Auditor selected for the site type and scope, with a conflict-of-interest declaration
- Pre-audit review of questionnaires, site master file, certificates and licences
- Audit plan agreed with you and the supplier in advance
Audit: evaluate on site, remotely or hybrid
Experienced professionals evaluate facilities, systems and records against the agreed requirements.
- Opening meeting to confirm scope and logistics
- Facility and system review
- Interviews with relevant personnel
- Closing meeting to confirm observations
Report: clear, graded and traceable
You receive a written report you can file directly into your quality system.
- Observations graded critical, major or minor
- Each observation traced back to the requirement
- Internal quality review before the report is released
Improve: turn findings into lasting compliance
We stay with the process until findings are addressed and evidence is assessed.
- Assessment of corrective and preventive action responses and evidence
- Closure report
- Recommended re-audit interval based on risk, history and findings
Deliverables
A complete, defensible record.
Every audit package is designed to be filed directly into your quality system.
Audit report
Written report with observations graded critical, major or minor.
Non-conflict declaration
A signed declaration of non-conflict of interest with every audit.
CAPA assessment
Corrective and preventive action plan and evidence assessed, where applicable.
Closure report
With a recommended re-audit interval based on risk, history and findings.
Supporting records
Attachments and referenced evidence filed with the report.
Auditor expertise
Matched to your supplier.
Each audit is led by an experienced pharmaceutical professional matched to the site type and scope, supported by wider technical expertise where needed.
Audit and consulting are kept separate. We do not assign an auditor to a site where prior involvement could compromise impartiality.
Shared audits and supplier qualification
Where a recent qualifying audit already exists, we manage access to the report in strict confidence, only with the consent of the audited site and report owner. You can also join an audit already planned. Your Quality Unit or QP always makes the final decision on acceptance.
Visit the Audit LibraryRegulatory framework
Standards we audit against.
| Area | Key references |
|---|---|
| API GMP | ICH Q7; EU GMP Part II (EudraLex Volume 4); PIC/S PE 009; MHRA Orange Guide |
| Quality system and risk | ICH Q9(R1) and Q10; EU GMP Chapter 1 and Chapter 7 |
| Starting materials, impurities, stability | ICH Q11, Q3A to Q3D, M7, Q1A; EMA and MHRA nitrosamine guidance |
| Sterile products | EU GMP Annex 1 (2022 revision) |
| Qualification and validation | EU GMP Annex 15 |
| Computerised systems and data integrity | EU GMP Annex 11; PIC/S, MHRA and WHO data integrity guidance |
| Qualified Person and batch certification | Directive 2001/83/EC; EU GMP Annex 16; UK Human Medicines Regulations 2012 |
| Distribution | EU Guidelines on GDP (2013/C 343/01); MHRA GDP requirements |
| Laboratories | OECD Principles of GLP; UK GLP Regulations 1999; ICH E6 for GCP |
| Medical devices | ISO 13485:2016; EU MDR 2017/745; UK Medical Devices Regulations 2002 |
| Audit practice | ISO 19011:2018 |
FAQ
Frequently asked questions.
What is a third-party GMP audit?
An independent assessment of a supplier, manufacturer, laboratory or service provider, carried out on behalf of a client, against applicable GMP and GxP requirements and the client's quality requirements. It supports supplier qualification, monitoring and risk decisions.
How do you ensure independence?
Every audit follows a documented independence and conflict-of-interest process. Auditors declare any actual, potential or perceived conflict before an engagement, and audit and consulting activities are kept separate.
Do you issue GMP certificates?
No. PharmaTrak does not issue regulatory GMP certificates. We provide independent audit reports and objective evidence that support qualification and compliance decisions.
Is a PharmaTrak audit report acceptable to my QP?
Our report gives your Quality Unit or Qualified Person independent evidence. Acceptance remains their decision and depends on scope, supplier risk and regulatory expectations. Where coverage is insufficient we may recommend a supplementary or focused audit.
Can you conduct remote or hybrid audits?
Yes, where scope and risk assessment show it is appropriate. Some activities need an on-site assessment so that facilities, equipment, utilities and material flows can be observed directly.
How do you protect confidential information?
Through confidentiality agreements, restricted access, controlled document sharing, secure transfer and access limited to authorised personnel. Specific requirements can be agreed per engagement.
Next step
